Margaret Mitchell1, Caroline Wells2, Xuechao Zhang3, Joshua Hughes1, Je'Purde White4, Robertson Nash5,6, David W Haas3,7. 1. Vanderbilt University, Nashville, TN, USA. 2. Lipscomb University College of Pharmacy, Nashville, TN, USA. 3. Vanderbilt University School of Medicine, Nashville, TN, USA. 4. Lipscomb University, Nashville, TN, USA. 5. Vanderbilt University School of Nursing, Nashville, TN, USA. 6. Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA. 7. Meharry Medical College, Nashville, TN, USA.
Abstract
AIM: Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills. METHODS: We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA. RESULTS: When told that switching from one pill to two or three pills "might make you feel a little better", 47% expressed definite or possible willingness. This decreased to 9% if there was "a small chance it might not control your HIV as well". Clinical variables were not associated with willingness. CONCLUSION: Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised.
AIM: Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills. METHODS: We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA. RESULTS: When told that switching from one pill to two or three pills "might make you feel a little better", 47% expressed definite or possible willingness. This decreased to 9% if there was "a small chance it might not control your HIV as well". Clinical variables were not associated with willingness. CONCLUSION: Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: David B Clifford; Scott Evans; Yijun Yang; Edward P Acosta; Karl Goodkin; Karen Tashima; David Simpson; David Dorfman; Heather Ribaudo; Roy M Gulick Journal: Ann Intern Med Date: 2005-11-15 Impact factor: 25.391
Authors: Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: Lucía Gallego; Pablo Barreiro; Rafael del Río; Daniel González de Requena; Apolinar Rodríguez-Albariño; Juan González-Lahoz; Vincent Soriano Journal: Clin Infect Dis Date: 2004-01-09 Impact factor: 9.079
Authors: Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245